Comparison of Efficacy of Terbinafine 1% Lotion and Cream Versus Clotrimazole 1% Solution and Cream in Otomycosis

Muhammad Sohail Zahid; Muhammad Tahir; Muhammad Atif Najam; Majid Dastgir; Ghulam Fareed; Abdul Hakim

doi:10.51253/pafmj.v76iSUPPL-9.13804

Authors

Muhammad Sohail Zahid Department of ENT, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Muhammad Tahir Department of ENT, Combined Military Hospital, Quetta/National University of Medical Sciences (NUMS) Pakistan
Muhammad Atif Najam Department of ENT, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Majid Dastgir Department of ENT, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Ghulam Fareed Department of ENT, Combined Military Hospital, Mangla/National University of Medical Sciences (NUMS) Pakistan
Abdul Hakim Department of ENT, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-9.13804

Keywords:

Clotrimazole, Dermatophytosis, External Ear Canal, Terbinafine

Abstract

Objective: To compare the efficacy of terbinafine 1% lotion and cream versus clotrimazole 1% solution and cream in otomycosis.

Study design: Quasi-experimental study.

Place and Duration of the study: ENT Department, Combined Military Hospital Multan, Pakistan from Apr to Dec 2023.

Methodology: A total of 66 cases of otomycosis were included. They were divided into Group-A (1% Terbinafine) and Group-B (1% Clotrimazole) based on laterality of the infection. Efficacy was analyzed in terms of achievement of complete cure and compared between the two groups.

Results: Median age was 39.00 (57.00 – 19.00) years. There were 24(36.36%) male and 42(63.64%) female patients. Median BMI was 29.85 (37.50 – 19.60) kg/m². There were 35(53.03%) patients who had diabetes, 7(10.61%) had hypertension and 7(10.61%) were smokers. Most common presenting symptom among patients diagnosed with otomycosis was ear itching 44(66.67%). Median pretreatment composite symptoms score was 3.00 (10.00 – 1.00). In Group-A (n=33), frequency of complete cure was 27 (81.82%), while in Group-B (n=33), it was 16 (48.48%); (p=0.004).

Conclusion: Terbinafine is significantly more efficacious as compared to clotrimazole in treatment of otomycosis.

Downloads

Download data is not yet available.

References

1. Kruithoff C, Gamal A, McCormick TS, Ghannoum MA. Dermatophyte infections worldwide: increase in incidence and associated antifungal resistance. Life 2023; 14(1): 1.

https://doi.org/10.3390/life14010001

2. Kashif S, Uddin F, Nasir F, Zafar S, Jabeen S, Kumar S. Prevalence of dermatophytes in superficial skin infections in a tertiary care hospital. J Pak Assoc Dermatol 2022 31(3): 484-488.

https://doi.org/10.66344/jpad.v31i3.1541

3. McCormick TS, Ghannoum M. Time to think antifungal resistance increased antifungal resistance exacerbates the burden of fungal infections including resistant dermatomycoses. Pathog Immun 2024; 8(2): 158-176.

https://doi.org/10.20411/pai.v8i2.656

4. Gupta AK, Mann A, Polla RS, Wang T. An update on antifungal resistance in dermatophytosis. Expert Opin Pharmacother 2024; 25(5): 511-519. https://doi.org/10.1080/14656566.2024.2343079

5. Sardana K, Gupta A, Mathachan SR. Immunopathogenesis of dermatophytoses and factors leading to recalcitrant infections. Indian Dermatol Online J 2021; 12(3): 389-399.

https://doi.org/10.4103/idoj.IDOJ_503_20

6. Brescini L, Fioriti S, Morroni G, Barchiesi F. Antifungal combinations in dermatophytes. J Fungi 2021; 7(9): 727.

https://doi.org/10.3390/jof7090727

7. Bojanović M, Stalević M, Arsić-Arsenijević V, Ignjatović A, Ranđelović M, Golubović M, et al. Etiology, predisposing factors, clinical features and diagnostic procedure of otomycosis: a literature review. J Fungi 2023; 9(6): 662.

https://doi.org/10.3390/jof9060662

8. Wu S, Cheng Y, Lin S, Liu H. A comparison of antifungal drugs and traditional antiseptic medication for otomycosis treatment: a systematic review and meta-analysis. Front Surg 2021; 8: 739360.

https://doi.org/10.3389/fsurg.2021.739360

9. Hudu SA, Saadi N, Morad EA, Tahir A, Jimoh AO. Pharmacological advances in Candida auris: emerging antifungal mechanisms and next-generation therapeutic strategies. J Enzyme Inhib Med Chem 2026; 41(1): 2660982.

https://doi.org/10.1080/14756366.2026.2660982

10. Lotfali E, Ghasemi R, Masoumi N, Molavizadeh D, Sadeghi S. Isolation, characterization, and antifungal sensitivity pattern of fungal species with potential resistance to antifungal drugs in patients with otomycosis. Arch Clin Infect Dis 2022; 17(4): e129169. https://doi.org/10.5812/archcid-129169

11. Mahmoudabadi AZ, Najafyan M, Moghimipour E, Alwanian M, Seifi Z. Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis. Iran J Micrbiol 2013; 5(1): 86-90.

12. Jain A, Dhamale S, Sardesai V. Factors responsible for difficult to treat superficial fungal infections: A study from a tertiary healthcare centre in India. Mycoses 2021; 64(11): 1442-1447.

https://doi.org/10.1111/myc.13301

13. Singla P, Garg S, Singh P, Sharma N, Mane P, Singh NK, et al. Clinicomycological profile and risk factors for dermatophytosis at a teaching tertiary care centre in north india: a cross-sectional study. Infect Disord Drug Targets 2023; 23(6): e280423216334.

https://doi.org/10.2174/1871526523666230428110207

14. Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol 2022; 20(9): 557-571. https://doi.org/10.1038/s41579-022-00720-1

15. Zeeshan F, Sabir M, Uddin F. The rising menace of antifungal resistance in dermatophytes among the patients of tinea capitis. J Pak Med Assoc 2023; 73(1): 43-48.

https://doi.org/10.47391/JPMA.5307

16. Asoegwu CN, Oladele RO, Kanu OO, Peters RF, Nwawolo CC. Clinical and microbiological profile of otomycosis in Lagos, Nigeria. Niger Postgrad Med J 2023; 30(2): 132-136.

https://doi.org/10.4103/npmj.npmj_9_23

17. Pereira M, Rao K, Sharin F, Tanweer F, Mair M, Rea P. Topical antibiotic-induced otomycosis - a systematic review of aetiology and risk factors. Indian J Otolaryngol Head Neck Surg 2024; 76(5): 3766-3776. https://doi.org/10.1007/s12070-024-04852-z

18. Abraham ZS. Aetiological profile, clinical features and risk factors for otomycosis in Dar Es Salaam, Tanzania: A cross-sectional study. Indian J Otolaryngol Head Neck Surg 2024; 76(5): 4133-4137.

https://doi.org/10.1007/s12070-024-04800-x

19. Alexander M, Cho E, Gliozheni E, Salem Y, Cheung J, Ichii H et al. Pathology of diabetes-induced immune dysfunction. Int J Mol Sci 2024; 25(13): 7105.

https://doi.org/10.3390/ijms25137105

20. Sogebi OA, Oyewole EA, Osinupebi OA. Clinicopathological study of otomycosis in a tertiary hospital in South-west Nigeria. Afr Health Sci 2024; 24(1): 69-75.

https://doi.org/10.4314/ahs.v24i1.9

21. Xu S, Li J, Ding L, Gao K, Xie F, Han J, et al. Efficacy and safety of terbinafine hydrochloride spray and 3% boric acid alcohol ear drops in otomycosis. Acta Otolaryngol 2020; 140(4): 302-306.

https://doi.org/10.1080/00016489.2020.1712474

22. Praveen SV, Munagala K, Mood N, Baddam GS. Efficacy of 7.5% povidone-iodine and 1% clotrimazole in the treatment of otomycosis – A prospective randomized study. Natl J Physiol Pharm Pharmacol 2022; 12(08): 1142-1146.

https://doi.org/10.5455/njppp.2022.12.12451202124122021

23. Shabbir Z, Ashfaq AH, Arshad M, Riaz N. Efficacy of pyodine soaked gelfoam vs single topical application of clotrimazole in treatment of otomycosis: a randomized controlled clinical trial. Indian J Otolaryngol Head Neck Surg 2024; 76(6): 5091-5097.

https://doi.org/10.1007/s12070-024-05076-x

24. Mohammed AH, Omer GA. Comparative study of topical 1% terbinafine cream versus 1% clotrimazole cream in the treatment of tineapedis. Diyala J Med 2023; 24(1): 177-184.

https://doi.org/10.26505/DJM.24016880824

25. Farah S, Sadaf J, Muhammad A, Muhammad FF. Efficacy of topical terbinafine and topical clotrimazolein the treatment of dermatophytosis and skin candidiasis; an observational study. Biostat Biometrics Open Acc J 2018; 4(3): 555637.

https://doi.org/10.19080/BBOAJ.2018.04.555637